Skip to Content

LivaNova PLC LIVN

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

LivaNova Maintains Stability in the Fourth Quarter; We Anticipate a Modest Recovery in 2021

Debbie S. Wang Senior Equity Analyst

Analyst Note

| Debbie S. Wang |

In the fourth quarter, narrow-moat LivaNova saw a continuation of the stabilization and improvement seen in the third quarter. For the full year, revenue growth and R&D expense came in slightly higher than expected, but this was offset by better-than-expected gross margin and S&GA expense, and we’re leaving our fair value estimate unchanged. As seen in earlier quarters, the greatest area of strength came from advanced circulatory support (up 53% versus the prior-year period) where treatment of COVID-19 patients has accelerated adoption of extracorporeal membrane oxygenation. Nonetheless, this wasn’t enough to steady the ship at LivaNova, as this product line only accounts for roughly 5% of consolidated revenue. The rest of the firm’s product segments remained hampered by declines in the quarter, with the most dramatic decreases in heart valves and cardiovascular, though the 6% fall in quarterly revenue was still considerably improved from the 34% dip seen in the second quarter.

Read Full Analysis

Company Profile

Business Description

U.K.-based LivaNova was born of a combination between Cyberonics in the U.S. and Sorin in Italy. The medical device firm is primarily focused on cardiovascular and cardiopulmonary solutions (with surgical heart valves, heart-lung machines, and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. LivaNova derives roughly half of its revenue from the U.S. market, another 21% from Europe, and the remainder from the rest of the world.

Contact
20 Eastbourne Terrace
London, W2 6LG, United Kingdom
T +44 2033250660
Sector Healthcare
Industry Medical Devices
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 4,000